Price T Rowe Associates Inc Alkermes Plc. Transaction History
Price T Rowe Associates Inc
- $867 Billion
- Q4 2024
A detailed history of Price T Rowe Associates Inc transactions in Alkermes Plc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 12,256,447 shares of ALKS stock, worth $432 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
12,256,447
Previous 12,998,606
5.71%
Holding current value
$432 Million
Previous $364 Million
3.12%
% of portfolio
0.04%
Previous 0.04%
Shares
17 transactions
Others Institutions Holding ALKS
# of Institutions
376Shares Held
173MCall Options Held
231KPut Options Held
158K-
Black Rock Inc. New York, NY29.1MShares$1.03 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.5MShares$652 Million0.01% of portfolio
-
State Street Corp Boston, MA8.81MShares$311 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY7.56MShares$266 Million3.55% of portfolio
-
Wellington Management Group LLP Boston, MA7.01MShares$247 Million0.04% of portfolio
About Alkermes plc.
- Ticker ALKS
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 164,254,000
- Market Cap $5.79B
- Description
- Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...